Memokath® 044TW Stent for Treatment of Urethral Stricture
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate if the placement of a temporary urethral stent for up to 12 months, following dilation or internal urethrotomy (cutting open), results in a higher rate of urethral patency during the first year of follow-up when compared to the control group that does not receive a stent.
| Condition | Intervention | Phase |
|---|---|---|
|
Urethral Stricture |
Device: Memokath stenting |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra |
- Stent/control effectiveness - urethral patency [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Peak urinary flow rate [ Time Frame: Immediate ] [ Designated as safety issue: No ]
- Re-intervention [ Time Frame: Short term ] [ Designated as safety issue: Yes ]
- Standard survey instruments (QOL, IPSS etc.) [ Time Frame: 15 mos ] [ Designated as safety issue: No ]
- Stent placement success [ Time Frame: immediate ] [ Designated as safety issue: Yes ]
- Stent removal success [ Time Frame: immediate ] [ Designated as safety issue: Yes ]
| Enrollment: | 92 |
| Study Start Date: | December 2002 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
-
Device: Memokath stenting
Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or internal urethrotomy with (treatment group) or without (control group) subsequent stenting. All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The stent is removed at one year. In case of premature stent removal the patient is also followed for up to one year unless further intervention is decided.
Control patients are offered the stent treatment option if the stricture recurs within the observation period but this group is separately analysed.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males > 21 years of age
Recurrent stricture of the bulbar urethra:
- < 50 mm in length on urethrography; and which
- has a segment unable to accommodate a 16Fr flexible cystoscope
- Healthy tissue on both sides of stent
- Urinary flow in the abnormal range of the Siroky nomogram.
- Written informed consent obtained prior to participation in the study
- Patients must be available for all follow-up visits.
Exclusion Criteria:
Strictures:
- outside the bulbous urethra
- associated with, or suspected to be, urethral carcinoma
- secondary to pelvic distraction injuries
- Inability to enlarge the bulbar urethral stricture to > 26 Fr.
- Presence of any other urologic implant
- Presence of urethral diverticuli
- History of hypospadias repair
- Presence or prior history of balanitis xerotica obliterans.
- Uncontrolled bleeding disorder
- Active urinary tract infection
- Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation.
- Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease
- Concurrent participation in another clinical investigation
- Current illness that might confound the results of this investigation
- Inability to participate in all of the necessary study activities
- Inability or unwillingness to return for all required follow-up visits
- Inability or unwillingness to sign the patient informed consent document
Contacts and Locations| United States, California | |
| Jack McAninch | |
| San Francisco, California, United States, 94110 | |
| United States, Mississippi | |
| Mississippi Urology | |
| Jackson, Mississippi, United States, 39202 | |
| United States, Ohio | |
| Cleveland Clinic | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| Bryn Mawr Urology | |
| Bryn Mawr, Pennsylvania, United States, 19010 | |
| United States, Rhode Island | |
| University Urological Associates | |
| Providence, Rhode Island, United States, 02904 | |
| United States, Virginia | |
| Devine-Tidewater Urology | |
| Norfolk, Virginia, United States, 23510 | |
| United States, Washington | |
| Harborview Medical Center | |
| Seattle, Washington, United States, 98104 | |
| Principal Investigator: | Gerry Jordan, MD | Sentara/Engineers and Doctors |
More Information
No publications provided
| Responsible Party: | Director of Clinical and Regulatory, Pnn Medical |
| ClinicalTrials.gov Identifier: | NCT00270504 History of Changes |
| Other Study ID Numbers: | 1-044TWUS |
| Study First Received: | December 23, 2005 |
| Last Updated: | November 17, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pnn Medical DK:
|
Memokath Urethral stricture urethral stent Bulbar urethral stricture |
Additional relevant MeSH terms:
|
Urethral Stricture Constriction, Pathologic Urethral Obstruction |
Urethral Diseases Urologic Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 23, 2013